SCHEMBL1982152

SCHEMBL1982152

COC(=O)N1CCCC(O)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
GRM3 Q14832 1/20 0.46
CHRNB2 P17787 2/20 0.43
CHRNA4 P43681 2/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
TSHR P16473 1/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
PDE4B Q07343 3/20 0.38
PDE4A P27815 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
POLB P06746 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14293314 1.00 CA12 (0.47) CA12CA1CA2CA9GRM3
SCHEMBL28416641 1.00 CA12 (0.47) CA12CA1CA2CA9GRM3
SCHEMBL6484170 0.88 CHRNB2 (0.46) CHRNB2CHRNA4CHRNB4CHRNA3SMN1; SMN2
SCHEMBL1942044 0.88 CHRNB2 (0.46) CHRNB2CHRNA4CHRNB4CHRNA3SMN1; SMN2
SCHEMBL3854429 0.88 CHRNB2 (0.46) CHRNB2CHRNA4CHRNB4CHRNA3SMN1; SMN2
SCHEMBL13864821 0.81 ALDH1A1 (0.50) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL8489223 0.81 ALDH1A1 (0.50) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL28171513 0.81 CA12 (0.47) CA12CA1CA2CA9GRM3
SCHEMBL7354982 0.81 CA12 (0.47) CA12CA1CA2CA9GRM3
SCHEMBL16426419 0.81 CA12 (0.47) CA12CA1CA2CA9GRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111171035-B Preparation method and application of 4-phenoxyphenyl pyrazolopyrimidine amide derivative 山东大学 2021-03-30 CN disclosed
CN-111171035-A Preparation method and application of 4-phenoxyphenyl pyrazolopyrimidine amide derivative 山东大学 2020-05-19 CN disclosed
US-9371275-B2 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis SWEDISH PHARMA AB (SE) 2016-06-21 US disclosed
US-9371275-B2 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis SWEDISH PHARMA AB (SE) 2016-06-21 US disclosed
US-9371275-B2 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis SWEDISH PHARMA AB (SE) 2016-06-21 US disclosed
US-20140100271-A1 NEW 5-AMINOLEVULINIC ACID PRODRUGS FOR USE IN PHOTODYNAMIC THERAPY AND PHOTODYNAMIC DIAGNOSIS SWEDISH PHARMA AB C/O INKUBERA AB (SE) 2014-04-10 US disclosed
US-20110223105-A1 NEW 5-AMINOLEVULINIC ACID PRODRUGS FOR USE IN PHOTODYNAMIC THERAPY AND PHOTODYNAMIC DIAGNOSIS SWEDISH PHARMA AB C/O INKUBERA AB (SE) 2011-09-15 US disclosed
US-20110223105-A1 NEW 5-AMINOLEVULINIC ACID PRODRUGS FOR USE IN PHOTODYNAMIC THERAPY AND PHOTODYNAMIC DIAGNOSIS SWEDISH PHARMA AB C/O INKUBERA AB (SE) 2011-09-15 US disclosed
US-20110223105-A1 NEW 5-AMINOLEVULINIC ACID PRODRUGS FOR USE IN PHOTODYNAMIC THERAPY AND PHOTODYNAMIC DIAGNOSIS SWEDISH PHARMA AB C/O INKUBERA AB (SE) 2011-09-15 US disclosed
EP-2337775-A1 NEW 5-AMINOLEVULINIC ACID PRODRUGS FOR USE IN PHOTODYNAMIC THERAPY AND PHOTODYNAMIC DIAGNOSIS Swedish Pharma AB (SE) 2011-06-29 EP disclosed
WO-2010024775-A1 NEW 5-AMINOLEVULINIC ACID PRODRUGS FOR USE IN PHOTODYNAMIC THERAPY AND PHOTODYNAMIC DIAGNOSIS SWEDISH PHARMA AB (SE) 2010-03-04 WO disclosed
US-6969712-B2 Benzimidazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-29 US disclosed
US-20040044056-A1 Benzimidazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-03-04 US disclosed
EP-1342717-A1 BENZIMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-09-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110223105-A1 NEW 5-AMINOLEVULINIC ACID PRODRUGS FOR USE IN PHOTODYNAMIC THERAPY AND PHOTODYNAMIC DIAGNOSIS ALAD, PKLR, ANXA5 CA12 2586/4885CA1 3728/4885CA2 2389/4885
US-20140100271-A1 NEW 5-AMINOLEVULINIC ACID PRODRUGS FOR USE IN PHOTODYNAMIC THERAPY AND PHOTODYNAMIC DIAGNOSIS ALAD, PPOX, ALDH7A1 CA12 1059/4885CA1 2183/4885CA2 975/4885
US-20040044056-A1 Benzimidazole derivatives GPR119, OPRL1, INSR CA12 3526/4885CA1 2325/4885CA2 2550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.